Urinary metabonomic study on colorectal cancer.

After our serum metabonomic study of colorectal cancer (CRC) patients recently published in J. Proteome Res., we profiled urine metabolites from the same group of CRC patients (before and after surgical operation) and 63 age-matched healthy volunteers using gas chromatography-mass spectrometry (GC-MS) in conjunction with a multivariate statistics technique. A parallel metabonomic study on a 1,2-dimethylhydrazine (DMH)-treated Sprague-Dawley rat model was also performed to identify significantly altered metabolites associated with chemically induced precancerous colorectal lesion. The orthogonal partial least-squares-discriminant analysis (OPLS-DA) models of metabonomic results demonstrated good separations between CRC patients or DMH-induced model rats and their healthy counterparts. The significantly increased tryptophan metabolism, and disturbed tricarboxylic acid (TCA) cycle and the gut microflora metabolism were observed in both the CRC patients and the rat model. The urinary metabolite profile of postoperative CRC subjects altered significantly from that of the preoperative stage. The significantly down-regulated gut microflora metabolism and TCA cycle were observed in postoperative CRC subjects, presumably due to the colon flush involved in the surgical procedure and weakened physical conditions of the patients. The expression of 5-hydroxytryptophan significantly decreased in postsurgery samples, suggesting a recovered tryptophan metabolism toward healthy state. Abnormal histamine metabolism and glutamate metabolism were found only in the urine samples of CRC patients, and the abnormal polyamine metabolism was found only in the rat urine. This study assessed the important metabonomic variations in urine associated with CRC and, therefore, provided baseline information complementary to serum/plasma and tissue metabonomics for the complete elucidation of the underlying metabolic mechanisms of CRC.

[1]  R. Abagyan,et al.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. , 2006, Analytical chemistry.

[2]  J. Collet,et al.  Use of antidepressants and risk of colorectal cancer: a nested case-control study. , 2006, The Lancet. Oncology.

[3]  Elaine Holmes,et al.  Susceptibility of human metabolic phenotypes to dietary modulation. , 2006, Journal of proteome research.

[4]  E. Holmes,et al.  Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. , 2008, Environmental microbiology.

[5]  Stefano Tiziani,et al.  Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. , 2009, Neoplasia.

[6]  A. Halabe Bucay The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. , 2007, Medical hypotheses.

[7]  U. Günther,et al.  Early Stage Diagnosis of Oral Cancer Using , 2009 .

[8]  D. Funch Predictors and Consequences of Symptom Reporting Behaviors in Colorectal Cancer Patients , 1988, Medical care.

[9]  Kyoungmi Kim,et al.  Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery*S , 2009, Molecular & Cellular Proteomics.

[10]  Rachel Cavill,et al.  Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). , 2009, Journal of proteome research.

[11]  Minjun Chen,et al.  Application of ethyl chloroformate derivatization for gas chromatography-mass spectrometry based metabonomic profiling. , 2007, Analytica chimica acta.

[12]  M. Pincus,et al.  Regulation of JNK signaling by GSTp , 1999, The EMBO journal.

[13]  C. Hew,et al.  Proteomic Analysis of Colorectal Cancer Reveals Alterations in Metabolic Pathways , 2006, Molecular & Cellular Proteomics.

[14]  J. Heddle,et al.  The potent colon carcinogen, 1,2-dimethylhydrazine induces mutations primarily in the colon. , 2004, Mutation research.

[15]  E. Gerner,et al.  Polyamine-mediated post-transcriptional regulation of COX-2. , 2002, Biochimie.

[16]  R P Bird,et al.  Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. , 1995, Cancer letters.

[17]  Z. Bentwich,et al.  Carcinoembryonic Antigen , 1978 .

[18]  W. Leung,et al.  Increasing incidence of colorectal cancer in Asia: implications for screening. , 2005, The Lancet. Oncology.

[19]  D. Salvadori,et al.  DNA damage and aberrant crypt foci as putative biomarkers to evaluate the chemopreventive effect of annatto (Bixa orellana L.) in rat colon carcinogenesis. , 2005, Mutation research.

[20]  A. Zauber,et al.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. , 1993 .

[21]  T. Selmer,et al.  p-Hydroxyphenylacetate decarboxylase from Clostridium difficile. A novel glycyl radical enzyme catalysing the formation of p-cresol. , 2001, European journal of biochemistry.

[22]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[23]  C. Vara-Thorbeck,et al.  Increased histidine decarboxylase (HDC) activity in human colorectal cancer: Results of a study on ten patients , 1988, Agents and Actions.

[24]  D. Barkla,et al.  Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. , 1982, British Journal of Cancer.

[25]  Tianlu Chen,et al.  Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. , 2009, Journal of proteome research.

[26]  G. Rechkemmer,et al.  Protective role of probiotics and prebiotics in colon cancer. , 2001, The American journal of clinical nutrition.

[27]  O. Fiehn,et al.  Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. , 2006, Cancer research.

[28]  A. Imperiale,et al.  Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning 1H magnetic resonance spectroscopy , 2009, Metabolomics.

[29]  R P Bird,et al.  Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. , 1987, Cancer letters.

[30]  C. Rice-Evans,et al.  Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. , 2004, Free radical biology & medicine.

[31]  S. Elsden,et al.  The end products of the metabolism of aromatic amino acids by clostridia , 1976, Archives of Microbiology.

[32]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[33]  Oliver Fiehn,et al.  Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover , 2008, Molecular Cancer.

[34]  C. Wolf,et al.  Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. , 1990, Carcinogenesis.

[35]  G. Balendiran,et al.  The role of glutathione in cancer , 2004, Cell biochemistry and function.